About this document
Darapladib in ACS: SOLID-TIMI 52 Results by Annisa Dwi Andriani is a document available to read on EtoBox.
The SOLID-TIMI 52 trial tested whether adding the drug darapladib to optimal medical therapy would reduce major coronary events in patients with a previous acute coronary syndrome (ACS). The trial randomized over 13,000 ACS patients within 30 days of hospitalization to darapladib 160mg daily or placebo. The primary endpoint was a composite of heart attack, cardiac death, or urgent coronary revascularization for chest pain or heart attack symptoms. The trial was led by an international executive committee an
- Author
- Annisa Dwi Andriani
- Language
- EN